Arrhythmogenic potential of positive inotropic agents

Basic Research in Cardiology

Volumn 95, Issue 3, 2000, Pages 186-198

  Stump, Gary L ^a   Wallace, Audrey A ^a   Gilberto, David B ^a   Gehret, John R ^a   Lynch Jr , Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Arrythmia; Myocardial infarction; Positive inotropic agent; Proarrhythmia; Programmed ventricular stimulation

Indexed keywords

4 [3 (1 BENZHYDRYL 3 AZETIDINYLOXY) 2 HYDROXYPROPOXY] 1H INDOLE 2 CARBONITRILE; 4 [3 (4 BENZHYDRYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY] 1H INDOLE 2 CARBONITRILE; DOBUTAMINE; FORSKOLIN; MILRINONE; OUABAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; DOG; FEMALE; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART STIMULATION; HEART VENTRICLE ARRHYTHMIA; MALE; MORTALITY; NONHUMAN; RISK FACTOR;

ANIMALS; ARRHYTHMIA; CARDIOTONIC AGENTS; DOGS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEART; HEART RATE; HEMODYNAMIC PROCESSES; MYOCARDIAL INFARCTION; TACHYCARDIA, VENTRICULAR; VENTRICULAR FUNCTION, LEFT;

EID: 0034128122     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003950050181     Document Type: Article

References (52)

1. Amos GJ, Ravens U (1994) The inotropic agents DPI 201-106 and BDF 9148 differentially affect potassium currents of guinea pig ventricular myocyte. Naunyn-Schmiedeberg's Arch Pharmacol 350: 426-433
2. Baumgart D, Ehring T, Krajcar M, Skyschally A, Heusch G (1994) Characterization of the inotropic and arrhythmogenic action of the sodium channel activator BDF 9148: a comparison to its S-enantiomer, to its congener DPI 201-106, to norepinephrine and to ouabain. Basic Res Cardiol 89: 61-79
3. Benedict CR (1993) The QT interval and drug-associated torsade de pointes. Drug Invest 5: 69-79
4. Bhandari AK, Widerhorn J, Sager PT, Leon C, Hong R, Kotlewski A, Hackett J, Rahimtoola SH (1992) Prognostic significance of programmed ventricaul stimulation in patients surviving complicated acute myocardial infarction: A prospectve study. Am Heart J 124: 87-96
5. Bourke JP, Richards DB, Ross DL, Wallace EM, McGuire MA, Uther JB (1991) Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 18: 780-791
6. Brembilla-Perrot B, Jacquemin L, de la Chaise AT, Beurrier D (1996) Programmed ventricular stimulation after myocardial infarction does not help reduce the risk of ventricular events. Cardiovasc Drugs Ther 10: 549-556
7. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets DL, White BG for the Vesnarinone Trial Investigators (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Eng J Med 339: 1810-1816
8. Cowley AJ, Skene AM on behalf of the Enoximone Investigators (1994) Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J 72: 226-230
9. DeBakker JMT, van Capelle FJL, Janse MJ, Wilde AAM, Coronel R, Becker AE, Dingemans KP, van Hemel NM, Hauer RNW (1988) Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 77: 589-606
10. Denniss AR, Richards DA, Cody DV, Russell PA, Young AA, Cooper MJ, Ross DL, Uther JB (1986) Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 74: 731-745
11. Dies F, Krell MJ, Whitlow P, Liang C-S, Goldenberg I, Applefield MM, Gilbert EM (1986) Intermittent dobutamine in ambulatory outpatients with chronic cardiac-failure. Circulation 74: II-38
12. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arenberg D, Baker A, Friedman L, Green HL, Huther ML, Richardson DW and the CAST Investigators (1991) Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia suppression trial. N Engl J Med 324: 781-788
13. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W (1981) Early phase acute myocardial infarct size quantitation. Validation of the triphenyltetrazolium chloride tissue enzyme staining technique. Am Heart J 101: 593-600
14. Gross GJ, Warltier DC, Hardman HF, Somani P (1977) The effect of ouabain on nutritional circulation and regional myocardial blood flow. Am Heart J 93: 487-495
15. Hamer A, Vohra J, Hunt D, Sloman G (1982) Prediction of sudden death by electrophysiologic studies in high-risk patients surviving yocardial infarction. Am J Cardiol 50: 223-229
16. Hirasawa A, Awaji T, Hosono M, Haruno A, Hashimoto K (1993) Effects of a new forskolin derivative, NKH477, on canine ventricular arrhythmia models. J Cardiovasc Pharmacol 22: 847-851
17. Iesaka Y, Nogami A, Aonuma K, Nitta J, Chun Y-H, Fujiwara H, Hiraoka M (1990) Prognostic significance of sustained monomorphic ventricular tachycardia induced by programmed ventricular stimulation using up to triple extrastimuli in survivors of acute myocardial infarction. Am J Cardiol 65: 1057-1063
18. Kou WH, Nelson SD, Lynch JJ, Montgomery DG, Hassan T, Lucchesi BR (1987) Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period. Evaluation in a conscious canine model of sudden death. J Am Coll Cardiol 9: 359-365
19. Kramer JB, Saffitz JE, Witkowski FX, Corr PB (1985) Intramural reentry as a mechanism of ventricular tachycardia during evolving canine myocardial infarction. Circ Res 56: 736-754
20. Lehedinsky Y, Nordstrom ST, Aschoff SE, Kapples JF, O'Malley GJ, Kosley RW, Fielding S, Hubbard JW (1992) Cardiotonic and coronary vasodilator responses to milrinone, forskolin and analog P87-7692 in the anesthetized dog. J Cardiovasc Pharmacol 19: 779-789
21. Leor J, Goldbourt U, Rabinowitz B, Reicher-Reiss H, Boyko V, Kaplinsky E, Behar S, and the SPRINT Study Group (1995) Digoxin and increased mortality among patients recovering from acute myocardial infarction. Importance of digoxin dose. Cardiovasc Drugs Ther 9: 723-729
22. Levi AJ, Dalton GR, Hancox JC, Mitcheson JS, Issberner J, Bates JA, Evans SJ, Howarth FC, Hobai IA, Jones JV (1997) Role of intracellular sodium overload in the genesis of cardiac arrhythmias. J Cardiovasc Electrophysiol 8: 7001-721
23. Lubbe WF, Podzuweit T, Daries PS, Opie LH (1978) The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart. J Clin Invest 61: 1260-1269
24. Lynch JJ, Kitzen JM, Hoff PT, Lucchesi BR (1988) Effects of pimobendan (UDCG-115 BS), a new positive inotropic agent, on ventricular tachycardia and ischemic ventricular fibrillation in a conscious canine model of recent myocardial infarction. J Cardiovasc Pharmacol 12: 547-554
25. Lynch JJ, Montgomery DG, Lucchesi BR (1986) Facilitation of lethal ventricular arrhythmias by therapeutic digoxin in conscious postinfarction dogs. Am Heart J 111: 883-890
26. Lynch JJ, Uprichard ACG, Frye JW, Driscoll EM, Kitzen JM, Lucchesi BR (1989) Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. J Cardiovasc Pharmacol 14: 585-597
27. Lynch JJ, Wallace AA, Stump GL, Stupienski RF III, Kothstein T, Gehret JR (1996) Differential efficacy of the Class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction. J Pharmacol Exp Ther 277: 671-678
28. Marchlinski FE, Buxton AE, Waxman HL, Josephson ME (1983) Identifying patients at high risk of sudden death after myocardial infarction: value of the response to programmed stimulation, degree of ventricular ectopic activity and severity of left ventricular dysfunction. Am J Cardiol 52: 1190-1196
29. Moss AJ, Davis HT, Conard DL, DeCamilla JJ, Odoroff CL (1981) Digitalis-associated cardiac mortality after myocardial infarction. Circulation 64: 1150-1155
30. Munger MA, Furniss SM (1997) Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? An antagonist viewpoint. Ann Pharmacother 31: 893-896
31. Noble J, Farrer M, McComb JM (1993) Flosequinan and arrhythmogenesis. Lancet 341: 1100
32. Novosel D, Hof A, Zierhut W, Hof RP (1993) Proarrhythmic effects of DPI 201-106 elicited with programmed ventricular stimulation: a comparison with sotalol. J Cardiovasc Pharmacol 21: 967-972
33. Ozaki T, Uematsu T, Nagashima S, Nishimoto M, Nakashima M (1991) Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine. Naunyn-Schmiedeberg's Arch Pharmacol 344: 478-487
34. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL for the PROMISE Study Research Group (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468-1475
35. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M and the PROFILE Investigators and Coordinators (1993) Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE Study. Circulation 88: I-301
36. Richards DA, Cody DV, Denniss AR, Russell PA, Young AA, Uther JB (1983) Ventricular electrical instability: a predictor of death after myocardial infarction. Am J Cardiol 51: 75-80
37. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent M for the SADS Foundation Task Force on LQTS (1996) Multiple mechanisms in the Long QT Syndrome. Current knowledge, gaps and future directions. Circulation 94: 1996-2012
38. Roy D, Marchand E, Theroux P, Waters DD, Pelletier GB, Bourassa MG (1985) Programmed ventricular stimulation in survivors of an acute myocardial infarction. Circulation 72: 487-494
39. Stevenson LW (1998) Inotropic therapy for heart failure. N Engl J Med 339: 1848-1850
40. Thandroyen FT, Maooris AC, Hagler HK, Ziman B, Pai L, Willerson JT, Buja LM (1991) Intracellular calcium transients and arrhythmia in isolated heart cells. Circ Res 69: 810-819
41. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525-533
42. The Digitalis Subcommittee of the Multicenter Post-Infarction Research Group (1987) The mortality risk associated with digitalis treatment after myocardial infarction. Cardiovasc Drugs Ther 1: 125-132
43. The Pimobendan in Congestive Heart Failure (PICO) Investigators (1996). Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) Trial. Heart 76: 223-231
44. The Xamoterol in Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336: 1-6 [Erratum, (1990) Lancet 336: 698]
45. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ (1995) Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Progr Cardiovasc Dis 38: 167-180
46. Todt H, Krumpl G, Krejcy K, Schunder-Tatzber S, Raberger G (1990) Programmed electrical stimulation in conscious dogs: electropharmacologic testing of amrinone. Arch Int Pharmacodyn 307: 32-48
47. Trolese-Mongheal Y, Barthelemy J, Paire M, Duchene-Marullaz P (1992) Arrhythmogenic potencies of amrinone and milrinone in unanesthetized dogs with myocardial infarct. Gen Pharmacol 23: 95-104
48. Tuttle RR, Mills J (1975) Development of a new catecholamine to selectively increase cardiac contractility. Circ Res 36: 185-196
49. Vatner SF, Baig H, Manders WT, Murray PA (1978) Effects of a cardiac glycoside on regional function, blood flow and electrograms in conscious dogs with myocardial infarction. Circ Res 43: 413-423
50. Vivaldi MT, Kloner RA, Schoen FJ (1985) Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol 121: 522-530
51. Wallace AA, Stupienski RF, Kothstein T, Gehret JR, Lynch JJ (1993) Demonstration of proarrhythmic activity with the Class IC agent encainide in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 21: 397-404
52. Zoni-Berisso M, Molini D, Mela GS, Vecchio C (1996) Value of programmed ventricular stimulation in predicting sudden death and sustained ventricular tachycardia in survivors of acute myocardial infarction. Am J cardiol 77: 673-680